Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 6,192 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (active placebo) Clear all
Active, not recruiting Phase 2 Interventional

Daily Topical Rapamycin for Vitiligo

NCT05342519
View directory record Official record
Conditions
Vitiligo
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Radicle Clarity DSTTM: A Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes

NCT07342192
View directory record Official record
Conditions
Cognitive Function
Interventions
Clarity Product Placebo Control, RS Clarity Active Product
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
35 Years to 60 Years
Enrollment
990 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Withdrawn Phase 4 Interventional

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

NCT01180764
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza (Omega-3 acid ethyl esters), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

NCT00679263
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

NCT02284893
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

NCT00499967
View directory record Official record
Conditions
Genital Warts
Interventions
GS-9191 ointment, GS-9191, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2009 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

NCT07456800
View directory record Official record
Conditions
Pharmacokinetic Analysis
Interventions
Deupirfenidone, Pirfenidone (PFD), Placebo
Drug
Lead sponsor
PureTech
Industry
Eligibility
60 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Lake Mary, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Terminated Phase 2 Interventional Results available

A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)

NCT01312844
View directory record Official record
Conditions
Depression
Interventions
Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT05276063
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions
Linsitinib, Placebo
Drug
Lead sponsor
Sling Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

NCT06477406
View directory record Official record
Conditions
Endometriosis
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional Results available

Oxytocin and Approach-avoid in Grief

NCT04505904
View directory record Official record
Conditions
Prolonged Grief Disorder, Bereavement
Interventions
Syntocinon, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
55 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

NCT06605599
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Dothan, Alabama • Anaheim, California • Colton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Methylsulfonylmethane on Knee Laxity

NCT03747198
View directory record Official record
Conditions
Ligament Injury, Ligament; Laxity, Tendon Rupture, Tendon Injuries
Interventions
methylsulfonylmethane, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 1, 2026, 9:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beetroot Juice and Sleep

NCT05864521
View directory record Official record
Conditions
Healthy
Interventions
Active Beetroot Juice Supplement (aBRJ), Placebo Beetroot Juice Supplement (pBRJ)
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DSM265 Prophylaxis of Plasmodium Falciparum Malaria

NCT02562872
View directory record Official record
Conditions
Healthy
Interventions
DSM265, Placebo, Sporozoites, Infective mosquito bite
Drug · Biological
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Impact of Different Sugar Replacer Combinations on Gastrointestinal Tolerance

NCT05794100
View directory record Official record
Conditions
Tolerance, Healthy Population
Interventions
Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator
Other
Lead sponsor
Mondelēz International, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 1, 2026, 9:26 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

NCT02574637
View directory record Official record
Conditions
Crohn's Disease
Interventions
Brazikumab IV Infusion, Brazikumab SC Injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

NCT04006145
View directory record Official record
Conditions
NAFLD, NASH
Interventions
Elobixibat, Placebo oral tablet
Drug
Lead sponsor
Albireo
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Canoga Park, California • Rialto, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 3 Interventional

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

NCT01617200
View directory record Official record
Conditions
Schizophrenia
Interventions
Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 1, 2026, 9:26 AM EDT
Recruiting Phase 2 Interventional

Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)

NCT06866275
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
KZ101, Placebo
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
5 Years to 14 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Orange, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 1, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

NCT00308581
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 1, 2026, 9:26 AM EDT
Withdrawn Not applicable Interventional

Reproductive Aging and Obstructive Sleep Apnea

NCT01850992
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Active CPAP, Sham CPAP
Device
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 70 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 1, 2026, 9:26 AM EDT